AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29116126 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic polygenic risk scores (PRS) for schizophrenia, bipolar disorder, BMI, waist‐hip‐ratio, insulin resistance and height, gene co‐expression modules from WGCNA
Number of subjects: 284
Study 26285130 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram and statins together
Number of subjects: 446
Study 26285130 — intervention group
Group type: COMPARATOR
Intervention: Neither medication
Number of subjects: 446
Study 26285130 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 446
Study 26285130 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipophilic statins
Number of subjects: 446
Study 26285130 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 446
Study 23331081 — intervention group
Group type: COMPARATOR
Intervention: Buccal infiltration (BI) group: 40 patients received supplemental BI of 0.9 mL of 4% articaine with 1 : 100,000 epinephrine.
Number of subjects: 80
Study 23331081 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal plus lingual infiltration (BLI) group: 40 patients received supplemental BI of 0.9 mL of 4% articaine with 1 : 100,000 epinephrine and LIs with the same anaesthetic solution and dose.
Number of subjects: 80
Study 21417518 — intervention group
Group type: EXPERIMENTAL
Intervention: Active maintenance of memory traces
Number of subjects: 0
Study 21417518 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive load
Number of subjects: 0
Study 18559401 — intervention group
Group type: EXPERIMENTAL
Intervention: TAAG intervention
Number of subjects: 0
Study 18559401 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity programs in intervention schools
Number of subjects: 0
Study 18559401 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 0
Study 17143239 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (n = 14)
Number of subjects: 18
Study 17143239 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (n = 4)
Number of subjects: 18
Study 17143239 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (both types)
Number of subjects: 18
Study 14611705 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt restricted mothers (n = 76)
Number of subjects: 404
Study 14611705 — intervention group
Group type: COMPARATOR
Intervention: Control mothers (n = 328)
Number of subjects: 404
Study 14611705 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Salt restricted and Control)
Number of subjects: 404
Study 11759870 — intervention group
Group type: COMPARATOR
Intervention: Non-porous teflon barrier membrane plus demineralized freeze dried bone allograft (DFDBA)
Number of subjects: 24
Study 11759870 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous teflon barrier membrane plus demineralized freeze dried bone allograft (DFDBA)
Number of subjects: 24
Study 9387969 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline (1.5 g)
Number of subjects: 62
Study 9387969 — intervention group
Group type: COMPARATOR
Intervention: Bleomycin (60 mg)
Number of subjects: 62
Study 9387969 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin
Number of subjects: 62
Study 9387969 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 62
Study 7910473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg day‐1)
Number of subjects: 12
Study 7910473 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg day‐1)
Number of subjects: 12
Study 7910473 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (40 mg day‐1)
Number of subjects: 12
Study 7910473 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 12
Study 3352332 — intervention group
Group type: EXPERIMENTAL
Intervention: E5 scale (five-point scale ranging from 'excellent' to 'poor')
Number of subjects: 499
Study 3352332 — intervention group
Group type: COMPARATOR
Intervention: S6 scale (six-point response scale ranging from 'very satisfied' to 'very dissatisfied')
Number of subjects: 499
Study 31257092 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (30-min sessions of 2 mAmp direct current over the dorsolateral prefrontal cortex, 5 days per week, for 3 weeks)
Number of subjects: 20
Study 31257092 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 20
Study 31257092 — intervention group
Group type: COMPARATOR
Intervention: Sham-control (sham stimulation with current turned off after 30 seconds)
Number of subjects: 20
Study 31257092 — intervention group
Group type: COMPARATOR
Intervention: Sham-control
Number of subjects: 20
Study 27527398 — intervention group
Group type: EXPERIMENTAL
Intervention: RME+WRDT
Number of subjects: 1659
Study 27527398 — intervention group
Group type: COMPARATOR
Intervention: RME-only
Number of subjects: 1659
Study 25716362 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-brain radiotherapy (WBRT) after high-dose methotrexate (HDMTX)-based chemotherapy
Number of subjects: 410
Study 25716362 — intervention group
Group type: COMPARATOR
Intervention: High-dose methotrexate (HDMTX)-based chemotherapy alone
Number of subjects: 410
Study 23590840 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy bipolar offspring (HBO)
Number of subjects: 31
Study 23590840 — intervention group
Group type: COMPARATOR
Intervention: Healthy control (HC)
Number of subjects: 31
Study 21714640 — intervention group
Group type: EXPERIMENTAL
Intervention: Late initiation of parenteral nutrition (not initiated before day 8)
Number of subjects: 4640
Study 21714640 — intervention group
Group type: EXPERIMENTAL
Intervention: Late initiation of parenteral nutrition
Number of subjects: 4640
Study 21714640 — intervention group
Group type: COMPARATOR
Intervention: Early initiation of parenteral nutrition (initiated within 48 hours after ICU admission)
Number of subjects: 4640
Study 19662781 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative epidural clonidine
Number of subjects: 0
Study 19662781 — intervention group
Group type: COMPARATOR
Intervention: Preoperative levobupivacaine
Number of subjects: 0
Study 19662781 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 0
Study 16757526 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) supplementation
Number of subjects: 54
Study 15342289 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide infusions at dosages of 0.005 or 0.01 microg/kg/min for 12 weeks
Number of subjects: 210
Study 15342289 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 210
Study 10926959 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Care Pathway (ICP) care coordinated by an experienced nurse
Number of subjects: 152
Study 10926959 — intervention group
Group type: COMPARATOR
Intervention: Conventional multidisciplinary care
Number of subjects: 152
Study 8604440 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter monitor (HM) limb
Number of subjects: 215
Study 8604440 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiologic study (EPS) limb
Number of subjects: 215
Study 8604440 — intervention group
Group type: EXPERIMENTAL
Intervention: EPS testing with concordant versus discordant efficacy prediction
Number of subjects: 215
Study 8604440 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive versus invasive limbs in ESVEM
Number of subjects: 215
Study 1390333 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bepridil (2 mg/kg)
Number of subjects: 38
Study 1390333 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bepridil (500 mg/day)
Number of subjects: 38
Study 1390333 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bepridil (900 mg/day)
Number of subjects: 38
Study 1390333 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bepridil (300 mg/day)
Number of subjects: 38
Study 1390333 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bepridil (600 mg/day)
Number of subjects: 38
Study 3935405 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-glibenclamide combination therapy
Number of subjects: 18
Study 3935405 — intervention group
Group type: COMPARATOR
Intervention: Insulin-placebo treatment
Number of subjects: 18
Study 30964413 — intervention group
Group type: EXPERIMENTAL
Intervention: Anopheles gambiae s.l. in rural areas
Number of subjects: 10367
Study 30964413 — intervention group
Group type: EXPERIMENTAL
Intervention: Culex quinquefasciatus in urban areas
Number of subjects: 10367
Study 30964413 — intervention group
Group type: COMPARATOR
Intervention: Indoor Residual Spraying (IRS)
Number of subjects: 10367
Study 29117299 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose triamcinolone acetonide (40 mg)
Number of subjects: 32
Study 29117299 — intervention group
Group type: COMPARATOR
Intervention: Low-dose triamcinolone acetonide (20 mg)
Number of subjects: 32
Study 27056132 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin-naphthoquine (AN)
Number of subjects: 230
Study 27056132 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 230
Study 27056132 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of P. vivax asexual forms
Number of subjects: 230
Study 27056132 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline P. falciparum gametocytaemia
Number of subjects: 230
Study 27056132 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline P. vivax gametocytaemia
Number of subjects: 230
Study 24851040 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg
Number of subjects: 19
Study 24851040 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 20 mg
Number of subjects: 19
Study 24851040 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 80 mg/day
Number of subjects: 19
Study 24851040 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of isosorbide dinitrate and ibuprofen
Number of subjects: 19
Study 22892744 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% liquid CHX
Number of subjects: 45
Study 22892744 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% gel CHX
Number of subjects: 45
Study 22892744 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control group)
Number of subjects: 45
Study 20159177 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous use of 30 mcg ethinylestradiol and 3 mg drospirenone for 168 days
Number of subjects: 78
Study 20159177 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous use of 30 mcg ethinylestradiol and 3 mg drospirenone
Number of subjects: 78
Study 20159177 — intervention group
Group type: COMPARATOR
Intervention: Cyclic use of 30 mcg ethinylestradiol and 3 mg drospirenone for six 28‐day cycles
Number of subjects: 78
Study 20159177 — intervention group
Group type: COMPARATOR
Intervention: Cyclic use of 30 mcg ethinylestradiol and 3 mg drospirenone
Number of subjects: 78
Study 17646619 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-cm² rivastigmine patch (9.5 mg/24 hours)
Number of subjects: 1195
Study 17646619 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-cm² rivastigmine patch (17.4 mg/24 hours)
Number of subjects: 1195
Study 17646619 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mg BID rivastigmine capsules
Number of subjects: 1195
Study 17646619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1195
Study 15789954 — intervention group
Group type: EXPERIMENTAL
Intervention: Any dental visit
Number of subjects: 873
Study 15789954 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrective treatment
Number of subjects: 873
Study 15789954 — intervention group
Group type: EXPERIMENTAL
Intervention: Denture visit
Number of subjects: 873
Study 15789954 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction
Number of subjects: 873
Study 15789954 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental cleaning (for stained teeth subgroup)
Number of subjects: 873
Study 12448042 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-Based Medicine (EBM)
Number of subjects: 0
Study 10189977 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 51
Study 10189977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 9506733 — intervention group
Group type: COMPARATOR
Intervention: Methimazole alone (group 1)
Number of subjects: 199
Study 9506733 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole plus T4 to maintain TSH in upper normal range (group 2)
Number of subjects: 199
Study 9506733 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole plus T4 to suppress TSH below 0.6 mIU/L (group 3)
Number of subjects: 199
Study 9506733 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (TSH < 1.0)
Number of subjects: 199
Study 9506733 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (methimazole alone)
Number of subjects: 199
Study 9506733 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (TSH > or = 1.0)
Number of subjects: 199
Study 1770419 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate mouthrinse (CHX)
Number of subjects: 30
Study 1770419 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile water
Number of subjects: 30
Study 1770419 — intervention group
Group type: COMPARATOR
Intervention: Non-irrigated controls
Number of subjects: 30
Study 6579838 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical application of 0.5 mg of prostaglandin E2 (PGE2) in 2 ml of gel
Number of subjects: 60
Study 6579838 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal application of 4 mg of prostaglandin E2 (PGE2) in 3 ml of gel
Number of subjects: 60
Study 31898663 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 fractions/week of RT (46 Gy/23 fractions/26 days) with injection Cisplatin 40 mg/m2
Number of subjects: 46
Study 31898663 — intervention group
Group type: COMPARATOR
Intervention: 5 fractions/week of RT (46 Gy/23 fractions/31 days) with injection Cisplatin 40 mg/m2
Number of subjects: 46
Study 30148941 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital photographs used by expert evaluators to assess pressure lesions.
Number of subjects: 184
Study 30148941 — intervention group
Group type: COMPARATOR
Intervention: Nursing registries of patients with pressure lesions.
Number of subjects: 184
Study 26871847 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.0 μg/kg loading dose over 10 minutes, followed by 0.5 μg/kg/h maintenance)
Number of subjects: 40
Study 26871847 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 40
Study 26871847 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 40
Study 24766306 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple interventions (lectures, plays, traffic department intervention, fire department intervention, emergency medical service intervention)
Number of subjects: 535
Study 24766306 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intervention
Number of subjects: 535
Study 24766306 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 535
Study 22670617 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc pyrithione (ZPT) shampoo (n = 15)
Number of subjects: 31
Study 22670617 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (n = 15)
Number of subjects: 31
Study 21675032 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa 2 gm/day
Number of subjects: 94
Study 21675032 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa 1 gm/day
Number of subjects: 94
Study 21675032 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa 3 gm/day
Number of subjects: 94
Study 18609169 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral daily treatment with 0.5 mg cyanocobalamin, 0.8 mg folic acid and 3 mg vitamin B(6) for 4 months
Number of subjects: 209
Study 18609169 — intervention group
Group type: COMPARATOR
Intervention: Placebo (double-blind)
Number of subjects: 209
Study 16351809 — intervention group
Group type: EXPERIMENTAL
Intervention: Epi‐CH (carbon activated absorbing epirubicin)
Number of subjects: 60
Study 16351809 — intervention group
Group type: COMPARATOR
Intervention: Control (aqueous epirubicin)
Number of subjects: 60
Study 16351809 — intervention group
Group type: EXPERIMENTAL
Intervention: Epi‐CH
Number of subjects: 60
Study 16351809 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 11840441 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution MRI of the knee joint
Number of subjects: 0
Study 10376616 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate zidovudine
Number of subjects: 15422
Study 10376616 — intervention group
Group type: COMPARATOR
Intervention: Deferred zidovudine
Number of subjects: 15422
Study 10376616 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine plus didanosine
Number of subjects: 15422
Study 10376616 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine plus zalcitabine
Number of subjects: 15422
Study 10376616 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine alone
Number of subjects: 15422
Study 10376616 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine plus didanosine vs zidovudine plus zalcitabine
Number of subjects: 15422
Study 7599749 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (1.0-1.2 mg intravenous over 1-2 hours)
Number of subjects: 278
Study 7599749 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 278
Study 7599749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 1741918 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg/d oxytetracycline over a fortnight
Number of subjects: 27
Study 1741918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 6113618 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine
Number of subjects: 40
Study 6113618 — intervention group
Group type: COMPARATOR
Intervention: Trebenzomine
Number of subjects: 40
Study 31504412 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum-fixed energy shocks (360-360-360 J)
Number of subjects: 276
Study 31504412 — intervention group
Group type: COMPARATOR
Intervention: Low-escalating energy shocks (125-150-200 J)
Number of subjects: 276
Study 30811447 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease stages
Number of subjects: 256
Study 30811447 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical functioning
Number of subjects: 256
Study 30811447 — intervention group
Group type: EXPERIMENTAL
Intervention: Bodily pain
Number of subjects: 256
Study 30811447 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitality
Number of subjects: 256
Study 30811447 — intervention group
Group type: EXPERIMENTAL
Intervention: Social functioning
Number of subjects: 256
Study 30811447 — intervention group
Group type: EXPERIMENTAL
Intervention: High income status
Number of subjects: 256
Study 30811447 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher educational status
Number of subjects: 256
Study 30811447 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin ≥11g/dl
Number of subjects: 256
Study 30811447 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of CKD complications
Number of subjects: 256
Study 30811447 — intervention group
Group type: EXPERIMENTAL
Intervention: High family income
Number of subjects: 256
Study 28397754 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostrum bovinum supplementation (500 mg for 20 days)
Number of subjects: 16
Study 28397754 — intervention group
Group type: COMPARATOR
Intervention: Placebo (whey)
Number of subjects: 16
Study 26014800 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine (IIV)
Number of subjects: 0
Study 26014800 — intervention group
Group type: EXPERIMENTAL
Intervention: Live-attenuated influenza vaccine (LAIV)
Number of subjects: 0
Study 26014800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23964690 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-CRM(197)
Number of subjects: 668
Study 23964690 — intervention group
Group type: COMPARATOR
Intervention: PRP-T
Number of subjects: 668
Study 21402342 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen replacement therapy
Number of subjects: 2
Study 21402342 — intervention group
Group type: COMPARATOR
Intervention: Control group (postmenopausal women without IOTVA)
Number of subjects: 2
Study 19154574 — intervention group
Group type: EXPERIMENTAL
Intervention: Sci-B-Vac vaccine (2.5 microg)
Number of subjects: 28
Study 19154574 — intervention group
Group type: EXPERIMENTAL
Intervention: Sci-B-Vac vaccine (5.0 microg)
Number of subjects: 28
Study 19154574 — intervention group
Group type: EXPERIMENTAL
Intervention: Sci-B-Vac vaccine (2.5 microg or 5.0 microg)
Number of subjects: 28
Study 17366258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine use
Number of subjects: 470
Study 17366258 — intervention group
Group type: COMPARATOR
Intervention: Alcohol use
Number of subjects: 470
Study 17366258 — intervention group
Group type: COMPARATOR
Intervention: Heroin use
Number of subjects: 470
Study 15190957 — intervention group
Group type: EXPERIMENTAL
Intervention: IC14 (1 mg/kg or 4 mg/kg single doses; 4 mg/kg daily for 4 days; or 4 mg/kg on day 1 followed by 2 mg/kg daily for 3 days)
Number of subjects: 40
Study 15190957 — intervention group
Group type: EXPERIMENTAL
Intervention: IC14
Number of subjects: 40
Study 15190957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11434166 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS stimulated ability to nitrogen oxide production
Number of subjects: 20
Study 11434166 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous ability to nitrogen oxide production
Number of subjects: 20
Study 11434166 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen oxide index calculation
Number of subjects: 20
Study 9886901 — intervention group
Group type: EXPERIMENTAL
Intervention: tasosartan (100 mg/day)
Number of subjects: 24
Study 9886901 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 7987363 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity and cardiorespiratory fitness assessment
Number of subjects: 34
Study 2308263 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (a nonselective beta-1, beta-2 antagonist) during exercise
Number of subjects: 7
Study 2308263 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (a specific beta-1 antagonist) during exercise
Number of subjects: 7
Study 2308263 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 7